Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Insmed's BiRCh Trial Disappointment Triggers Selloff; Pivots to Monoclonal Antibody Platform
Insmed Inc. (INSM) faced a significant market disappointment after disclosing that its Phase 2b BiRCh trial for brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) failed to achieve both primary and secondary efficacy endpoints across the 10 mg and 40 mg dosing cohorts. The clinical setback prompted the company to immediately halt all development efforts for brensocatib in this indication.
Market Reaction and Stock Performance
Investor sentiment turned decidedly negative following the announcement, with INSM shares plummeting 21.39% in after-hours trading. The stock closure on Wednesday had already reflected some bearish pressure, finishing at $198.46, down 1.10% on the day. Over the trailing twelve-month period, INSM has oscillated between a low of $60.40 and a high of $212.75, painting a picture of volatility in the biopharmaceutical sector.
Strategic Pivot: INS1148 Acquisition
To offset the clinical failure, Insmed announced a strategic acquisition of INS1148 (previously designated OpSCF), a Phase 2-ready monoclonal antibody candidate originally developed by Opsidio, a private clinical-stage biotech firm. While acquisition terms remained undisclosed, the deal signals management’s commitment to redirecting resources toward alternative therapeutic pathways.
The company intends to advance INS1148 into Phase 2 development targeting two indications: interstitial lung disease and moderate-to-severe asthma—both representing significant unmet medical needs.
Company Commentary
Dr. Martina Flammer, M.D., MBA, Chief Medical Officer of Insmed, acknowledged the disappointment while framing the outcome constructively: “While we are disappointed in the results, they provided us with a clear answer. We extend our sincerest gratitude to the patients and investigators who made the BiRCh study possible.”
The acquisition represents management’s pragmatic approach to portfolio optimization, leveraging the acquired monoclonal antibody platform to pursue potentially more tractable respiratory and inflammatory targets.